Traduction de «Médicament chronique » (Français → Anglais) :

chronic use drug

atrophic arthritis | chronic inflammatory arthritis | proliferative arthritis | rheumatic gout | rheumatoid arthritis | RA [Abbr.]

special features editor

chronic psychiatric patient [ chronic mental patient ]

chronic obstructive lung disease | chronic obstructive pulmonary disease | COLD [Abbr.] | COPD [Abbr.]

Definition: This block contains a wide variety of disorders that differ in severity and clinical form but that are all attributable to the use of one or more psychoactive substances, which may or may not have been medically prescribed. The third character of the code identifies the substance involved, and the fourth character specifies the clinical state. The codes should be used, as required, for each substance specified, but it should be noted that not all fourth character codes are applicable to all substances. Identification of the psychoactive substance should be based on as many sources of information as possible. These include self-report data, analysis of blood and other body fluids, characteristic physical and psychological symptom ...[+++]s, clinical signs and behaviour, and other evidence such as a drug being in the patient's possession or reports from informed third parties. Many drug users take more than one type of psychoactive substance. The main diagnosis should be classified, whenever possible, according to the substance or class of substances that has caused or contributed most to the presenting clinical syndrome. Other diagnoses should be coded when other psychoactive substances have been taken in intoxicating amounts (common fourth character .0) or to the extent of causing harm (common fourth character .1), dependence (common fourth character .2) or other disorders (common fourth character .3-.9). Only in cases in which patterns of psychoactive substance-taking are chaotic and indiscriminate, or in which the contributions of different psychoactive substances are inextricably mixed, should the diagnosis of disorders resulting from multiple drug use (F19.-) be used. | Modifiers The following fourth-character subdivisions are for use with categories F10-F19: Code Title .0 Acute intoxication A condition that follows the administration of a psychoactive substance resulting in disturbances in level of consciousness, cognition, perception, affect or behaviour, o ...

chronic myeloid leukemia | chronic granulocytic leukaemia | chronic granulocytic leukemia | chronic myelocytic leukemia | chronic myelogenous leukaemia | chronic myelogenous leukemia

ethical drug | medicinal product subject to medical prescription | prescription drug | prescription medicine | prescription only medicine | prescription-only medicinal product | Rx drug | POM [Abbr.]

Laryngitis, chronic, with tracheitis (chronic) Tracheitis, chronic, with laryngitis

Chronic:bronchitis NOS | tracheitis | tracheobronchitis

In order to improve treatments available for vulnerable groups such as frail or older people, people suffering from multiple chronic conditions, and people affected by mental health disorders, medicinal products which are likely to be of significant clinical value should be fully and appropriately studied for their effects in these specific groups, including as regards requirements related to their specific characteristics and the protection of the health and well-being of subjects belonging to these groups.

M. whereas, furthermore, older patients and patients with immunodeficiencies or chronic diseases, in particular degenerative diseases, are especially vulnerable to healthcare-related adverse events, such as: diagnostic errors; lack of follow-up to medical examinations; the prescription, dispensing or administration of an inappropriate (e.g. off-label) medicine, of an incorrect dose or of two medicines which should not be combined; failure or poor decontamination of medical equipment; and infection of surgical scars;

M. whereas, furthermore, older patients and patients with immunodeficiencies or chronic diseases, in particular degenerative diseases, are especially vulnerable to healthcare-related adverse events, such as: diagnostic errors; lack of follow-up to medical examinations; the prescription, dispensing or administration of an inappropriate (e.g. off-label) medicine, of an incorrect dose or of two medicines which should not be combined; failure or poor decontamination of medical equipment; and infection of surgical scars;

‘vulnerable groups’ means those groups of the population most sensitive to measures determining the extent to which medicinal products are covered by public health insurance systems, such as children, pensioners, the unemployed, those reliant on orphan drugs and the chronically ill.